Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold shares of common stock on May 18, 2026, according to an SEC filing.
The transaction involved 3,115 shares at $13.04 each, totaling $40,619.
The sale was executed to cover tax withholding obligations from vesting restricted stock units (RSUs). This mandatory 'sell to cover' process is required under the company's equity incentive plans and was not a discretionary trade.
Following the sale, Piskel directly holds 256,725 shares. The stock currently trades at $13.95, up nearly 50% over the past year, though Bond.az analysis suggests it may be overvalued.
Adaptive Biotechnologies reported $295 million in revenue over the last twelve months with 56% growth, though it remains unprofitable.
